Geo Group Inc (The) REIT vs Vaxcyte Inc. Common Stock — how do they compare? Geo Group Inc (The) REIT trades at $30.87 (market cap $4.24B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.5× Geo Group Inc (The) REIT's market cap, and Vaxcyte Inc. Common Stock is more actively traded (2,644,694 versus 1,580,830). Which is the better fit depends on your goals — on Pluang, investors hold Geo Group Inc (The) REIT for 6 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| GEO | PCVX | |
|---|---|---|
Market Cap | $4.24B | $10.51B |
Volume | 1,580,830 | 2,644,694 |
Sector | Industrials | Health |
52-Week High | $32.77 | $73.82 |
52-Week Low | $13.26 | $40.32 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.79B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
GEO trades at $32.19, up 1.45% today, with a bullish technical signal from moving averages. Recent earnings beats in Q1 and Q2 2026, alongside a net income margin of 10.31% and ROE of 20.11%, highlight strong profitability. The company recently sold its Adelanto facilities for $950 million and increased its share repurchase authorization to $1.25 billion, signaling financial strength and shareholder returns.
The outlook is positive, supported by analyst consensus (66.7% buy ratings) and recent Zacks upgrades to Strong Buy. Key opportunities include earnings momentum and strategic asset sales, while risks involve debt management and potential regulatory scrutiny. The stock's valuation, with a P/E of 15.18, appears reasonable given growth prospects.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The GEO Group provides correctional, detention, and community reentry services. Its operations include secure facilities, electronic monitoring, and support programs for individuals in the criminal-justice system.
Read more on GEO →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →